Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma

被引:19
作者
Chen, Wei [1 ,2 ]
Shan, Boer [1 ,3 ]
Zhou, Shuling [3 ,4 ]
Yang, Huijuan [1 ,3 ]
Ye, Shuang [1 ,3 ]
机构
[1] Fudan Univ, Dept Gynecol Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Minhang Hosp, Dept Obstet & Gynecol, Cent Hosp Minhang Dist, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China
[4] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Ovarian neoplasms; Clear cell carcinoma; Fibrinogen; albumin ratio; Platinum resistance; Survival; DETERMINANT;
D O I
10.1186/s12885-022-09204-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background This study aims to evaluate the role of the fibrinogen/albumin ratio (FAR) in predicting platinum resistance and survival outcomes of patients with ovarian clear cell carcinoma (OCCC). Methods Coagulation function and D-dimer, serum albumin, CA125 and HE4 levels were measured before surgery in OCCC patients undergoing initial surgery in our institution. FAR was calculated as fibrinogen/albumin level. The correlation between these indicators and clinicopathological features, platinum response, and survival outcomes was further analyzed. The Kaplan-Meier method and multivariable Cox regression model were used to assess the effects of FAR on progression-free survival (PFS) and overall survival (OS). Results Advanced stage patients accounted for 42.1% of the 114 participants. Optimal cytoreductive surgery was achieved in 105 patients, and the complete resection rate was 78.1%. FAR was associated with tumor stage, residual tumor and platinum response. A receiver operating characteristic curve for predicting platinum response showed that the optimal cutoff point of the FAR was 12%. The sensitivity was 73.3% and the specificity was 68.2%. In multivariate analysis, FAR >= 12% (HR = 4.963, P = 0.002) was an independent risk factor for platinum resistance. In addition, FAR and D-dimer proved to be independent negative factors for outcomes including both PFS and OS. The median follow-up time was 52 months. A high FAR (>= 12%) showed a stronger correlation with poor OS and PFS in the subgroup analysis of advanced and completely resected patients. Conclusions The FAR might be a potential preoperative biochemical marker for predicting treatment response and oncological outcomes in OCCC patients.
引用
收藏
页数:10
相关论文
共 32 条
[1]   Aggressive surgical effort and improved survival in advanced-stage ovarian cancer [J].
Aletti, GD ;
Dowdy, SC ;
Gostout, BS ;
Jones, MB ;
Stanhope, CR ;
Wilson, TO ;
Podratz, KC ;
Cliby, WA .
OBSTETRICS AND GYNECOLOGY, 2006, 107 (01) :77-85
[2]   Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010 [J].
Anglesio, Michael S. ;
Carey, Mark S. ;
Koebel, Martin ;
MacKay, Helen ;
Huntsman, David G. .
GYNECOLOGIC ONCOLOGY, 2011, 121 (02) :407-415
[3]   The hypercoagulable state of malignancy: Pathogenesis and current debate [J].
Caine, GJ ;
Stonelake, PS ;
Lip, GYH ;
Kehoe, ST .
NEOPLASIA, 2002, 4 (06) :465-473
[4]   Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer [J].
Cham, Stephanie ;
Chen, Ling ;
St Clair, Caryn M. ;
Hou, June Y. ;
Tergas, Ana I. ;
Melamed, Alexander ;
Ananth, Cande V. ;
Neugut, Alfred I. ;
Hershman, Dawn L. ;
Wright, Jason D. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2019, 220 (06) :571.e1-571.e8
[5]   Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer [J].
Chang, Suk-Joon ;
Bristow, Robert E. ;
Ryu, Hee-Sug .
ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (13) :4059-4067
[6]   Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications [J].
Chen, Wei ;
Zhong, Siyuan ;
Shan, Boer ;
Zhou, Shuling ;
Wu, Xiaohua ;
Yang, Huijuan ;
Ye, Shuang .
JOURNAL OF OVARIAN RESEARCH, 2020, 13 (01)
[7]   What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? [J].
Chi, D. S. ;
Eisenhauer, E. L. ;
Lang, J. ;
Huh, J. ;
Haddad, L. ;
Abu-Rustum, N. R. ;
Sonoda, Y. ;
Levine, D. A. ;
Hensley, M. ;
Barakat, R. R. .
GYNECOLOGIC ONCOLOGY, 2006, 103 (02) :559-564
[8]   Clear cell carcinoma of the ovary: A review of the literature [J].
del Carmen, Marcela G. ;
Birrer, Michael ;
Schorge, John O. .
GYNECOLOGIC ONCOLOGY, 2012, 126 (03) :481-490
[9]   Fibrinogen/Albumin Ratio as a Promising Marker for Predicting Survival in Pancreatic Neuroendocrine Neoplasms [J].
Deng, Shengming ;
Fan, Zhiyao ;
Xia, Huanyu ;
Gong, Yitao ;
Qian, Yunzhen ;
Huang, Qiuyi ;
Cheng, He ;
Jin, Kaizhou ;
Xiao, Zhiwen ;
Luo, Guopei ;
Yu, Xianjun ;
Liu, Chen .
CANCER MANAGEMENT AND RESEARCH, 2021, 13 :107-115
[10]   Inflammation and cancer: What a surgical oncologist should know [J].
Dupre, Aurelien ;
Malik, Hassan Z. .
EJSO, 2018, 44 (05) :566-570